The outbreak was officially declared on 15 May 2026 in Ituri Province, after laboratory testing at the National Institute for Biomedical Research in Kinshasa confirmed the Bundibugyo strain . In roughly 14 weeks, it became the second-largest Ebola outbreak ever recorded—a speed that public health experts describe as unprecedented
.
This rapid pace is especially alarming because no approved vaccine or therapeutics exist for the Bundibugyo virus . Previous large Ebola outbreaks, including the 2014–2016 West Africa epidemic, were caused by the Zaire ebolavirus, for which effective vaccines (e.g., Ervebo) and treatments were eventually developed. The Bundibugyo strain has never been the subject of a licensed countermeasure.
Perhaps the most disturbing indicator of how far the outbreak has outstripped containment efforts is the breakdown in contact tracing. WHO officials have stated that 80% of new Ebola cases in eastern DRC are emerging from unknown chains of transmission with no link to known patients .
In mid-July, Dr. Chikwe Ihekweazu, the WHO's Executive Director of Health Emergencies, warned that the true scale of the outbreak could be two to four times larger than official data suggested . The Africa CDC's Director-General, Jean Kaseya, said in early August that nearly 70% of new infections were emerging outside known contact lists, a sign of widespread community transmission that standard containment measures are failing to detect
.
"The outbreak is moving faster than the response," Kaseya said, noting that treatment centres were already at saturation point as of early July .
On 16 July 2026, WHO Director-General Tedros Adhanom Ghebreyesus acknowledged that the outbreak had "continued to expand despite major efforts" and that intense transmission in Ituri province was outpacing the response capacity . He stated bluntly that the response itself is being "overwhelmed" and that the virus "continues to outpace the response efforts"
.
Despite significant scale-up—treatment capacity exceeding 800 beds, expansion from 1 to 16 laboratories, and the training of more than 21,000 community workers—the gap between response and need remains enormous . Dr. Rose Belizaire, the WHO Africa Emergency Response Lead, said in late June that the response was at "about three or four" on a scale of zero to ten
.
The outbreak is concentrated in Ituri Province in northeastern DRC, which accounts for nearly 90% of all cases . This region presents extraordinary challenges that are compounding the epidemic:
Two-thirds of deaths are occurring in communities among people who never received care in a health facility . This means the virus is spreading through unsafe burial practices, as bodies of deceased Ebola patients are highly infectious.
The international response has been substantial but insufficient. Key capacity metrics include:
The Africa CDC has launched a joint response coordination with WHO, but the nature of this outbreak—driven by community transmission in a conflict zone with no medical countermeasures—means that conventional containment strategies are failing.
For the general American public, the risk of importation is currently considered low, according to the CDC . Modeling suggests the likelihood of Ebola being imported into the United States is low at present, and if a case were imported, the risk of sustained secondary transmission in the United States is also low given the strength of the U.S. public health system
. However, the CDC has issued a Health Alert Network (HAN) Health Advisory to alert clinicians and public health practitioners
.
One case linked to the outbreak—a U.S. individual who had treated patients in the DRC—was reported in May . No further U.S. cases have been reported
.
The 2026 DRC Ebola outbreak is accelerating faster than any Ebola outbreak in history, driven by a strain for which no medical countermeasures exist, unfolding in a conflict zone where healthcare workers are unpaid and the response is overwhelmed. The official case count—3,605—may represent only a fraction of the true epidemic, which WHO modeling suggests could be two to four times larger. Without a vaccine, without dedicated therapeutics, and with the response already saturated, the window for containment is closing.